Business
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"text","content":"CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (\"Catalyst\" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Ms. Tamar Thompson to the Company's Board of Directors (\"Board\"), effective on May 25, 2023. \"We are extremely pleased to welcome Tamar to our Board as she brings a wealth of experience to our team across several therapeutic categories, including rare diseases, coupled with extensive health policy and government affairs acumen,\" said Patrick J. McEnany, Chairman and CEO of Catalyst. \"Ms. Thompson's distinguished industry expertise and leadership ideally align with Catalyst’s long-term growth strategy. We look forward to her valuable contributions as we continue executing our expansion initiatives to provide innovative rare neuroscience disease medicines to more patients seeking novel treatment options.\" \"I am honored to join the Catalyst Board at such a pivotal time in the Company’s history,\" said Ms. Thompson. \"Catalyst has experienced a very successful evolution over the last few years and is well positioned to further capitalize on its established capabilities with additional novel assets that complement its growing product portfolio. I look forward to collaborating with the Board and the Catalyst’s leadership team as the Company advances its strategic growth plans.\" Ms. Thompson has more than twenty years of leadership experience in health care, health policy strategy, government affairs, and market access, with a diverse background across multiple healthcare sectors and therapeutic categories, including rare diseases, with a focus on developing strategic and tactical recommendations to ensure optimal reimbursement and market access for rare disease products. Ms. Thompson currently serves as Vice President, Head of Global Corporate Affairs for Alexion Pharmaceutical, AstraZeneca Rare Diseases. Prior to joining Alexion, Ms. Thompson served as Executive Director, State Government Affairs and Federal Policy for Bristol-Myers Squibb Company. Prior to joining Bristol Myers Squibb, she served as a strategic policy advisor and consultant for various governmental affairs firms based in Washington, D.C. Ms. T...